Jelena S Rudic et al.
The Cochrane database of systematic reviews, 12, CD000551-CD000551 (2012-12-14)
Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis. To assess